No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ABBV AbbVie
- 171.360
- +1.680+0.99%
Close Jun 18 16:00 ET
- 171.360
- 0.0000.00%
Post 19:50 ET
302.60BMarket Cap51.00P/E (TTM)
173.010High169.870Low4.25MVolume170.440Open169.680Pre Close729.84MTurnover0.24%Turnover Ratio63.00P/E (Static)1.77BShares181.19652wk High37.79P/B301.94BFloat Cap125.84752wk Low5.99Dividend TTM1.76BShs Float181.196Historical High3.50%Div YieldTTM1.85%Amplitude20.362Historical Low171.690Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
AbbVie's Skyrizi Gets FDA Approval to Treat Certain Instances of Ulcerative Colitis
AbbVie said the U.S. Food and Drug Administration approved Skyrizi for adults diagnosed with moderately to severely active ulcerative colitis.
From Comfort to Cure: 2024 ASCO Meeting Reveals Groundbreaking Oncology Data
USA News Group – This year's 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) has now come and gone, but not without...
Why AbbVie (ABBV) Is a Great Dividend Stock Right Now
Here's Why AbbVie (ABBV) Is a Strong Momentum Stock
AbbVie's SKYRIZI Gains US FDA Approval for Ulcerative Colitis
ABBV.US's heavyweight IL-23 inhibitor has once again been approved by the FDA for the treatment of ulcerative colitis.
AbbVie (ABBV.US) announced that the FDA has approved its IL-23 inhibitor, Risankizumab, for the treatment of adult patients with moderate to severe active ulcerative colitis.
Comments
From YouTube
6
Interesting both for the (1) shift in the macro-trend to M&A (vs. Licensing) and (2) change in top spenders
$Merck & Co(MRK.US$ $Bristol-Myers Squibb(BMY.US$ $Johnson & Johnson(JNJ.US$ $Pfizer(PFE.US$ $Novo-Nordisk A/S(NVO.US$ $AbbVie(ABBV.US$
$Merck & Co(MRK.US$ $Bristol-Myers Squibb(BMY.US$ $Johnson & Johnson(JNJ.US$ $Pfizer(PFE.US$ $Novo-Nordisk A/S(NVO.US$ $AbbVie(ABBV.US$
10
1
Top 10 drug companies raked in NEARLY TRIPLE the revenue in 2023 ($491B) vs 2013 ($165B) 2013 vs. 2023.
$AbbVie(ABBV.US$ +189%
$Bristol-Myers Squibb(BMY.US$ +175%
$Johnson & Johnson(JNJ.US$ +95%
$AstraZeneca(AZN.US$ +78%
$NVM +45%
$Merck & Co(MRK.US$ +37%
$ROCHE HOLDING AG(RHHBY.US$ +27%
$Pfizer(PFE.US$ +13%
$GlaxoSmithKline(GSK.US$ +13%
----- $SPDR S&P 500 ETF(SPY.US$ +12% -----
$Sanofi(SNY.US$ +3%
Source: Arjun Murthy on the HR app!
$AbbVie(ABBV.US$ +189%
$Bristol-Myers Squibb(BMY.US$ +175%
$Johnson & Johnson(JNJ.US$ +95%
$AstraZeneca(AZN.US$ +78%
$NVM +45%
$Merck & Co(MRK.US$ +37%
$ROCHE HOLDING AG(RHHBY.US$ +27%
$Pfizer(PFE.US$ +13%
$GlaxoSmithKline(GSK.US$ +13%
----- $SPDR S&P 500 ETF(SPY.US$ +12% -----
$Sanofi(SNY.US$ +3%
Source: Arjun Murthy on the HR app!
7
1
Hello Mooers! ![]()
Recently, there have been signs that World War 3![]()
is coming (*1, *2, *3). Given the current status in the Middle East, Eastern Europe, and the Asia-Pacific, investing has become a difficult task. ![]()
In light of this hypothetical situation![]()
, I have chosen to invest from April 2024 to July 2024 using a three-pronged strategy. ![]()
![]()
![]()
Approach One: Buy the winners
Who are the winners?![]()
During wars, companies that are in the defense, oil, ...
Recently, there have been signs that World War 3
In light of this hypothetical situation
Who are the winners?
29
37
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg